Limón-Flores JA, Pérez-Lozano U, Solís PJC, Rodríguez-Castillo P, Zagoya-Martínez P, Lobato-Tolama RD, Olvera-Oropeza LO, Pavón-Vargas MÁ, Durán-Montoya R, González-Blanco MJ, López-Gil C, García-Castillo C

Language: Spanish
References: 11
Page: 179-184
PDF size: 71.69 Kb.

ABSTRACT

The haematopoietic stem cell transplantation program started in 1995 in our hospital following a development strategy from simplicity to complexity, beginning with autologous and continuing with allogeneic transplantation. To date we carried out 268 procedures, 145 autologous and 123 allotransplants on 131 children and 137 adults. Received bone marrow 77 patients, peripheral blood stem cells 163 and cord blood 28. Our program has applied 13 different conditioning regimens, mieloablative on 87% and reduced intensity on 13% of patients. We used total body irradiation on 55 cases. Regarding of autotransplants, the cellular preservation was based on 4°C simple refrigeration during 3-6 days achieving more than 70% viability. The series average follow up has reached 81 months. To date 57% are in continuous complete remission, 39% died and 4% are not in complete remission or lost follow up. Our team recommend starting transplantation programs inside the country following our experience from simplicity to complexity, has made evident cryopreservation is not mandatory in order to perform autotransplants, and consider exists an optimal specific transplant, conditioning regimen and stem cells source variety to each unique patient, regarding not pertinent serial patients management using just one procedure modality.

REFERENCES

1. Limón Flores JA, Gonzalez Pérez ME, Tolama RD. Jornadas de trasplante hematopoyético en el IMSS de Puebla. Resultados. Revista de Hematología 2004;5(Supl 1):S-11.

2. Köppler H, Pflüger KH, Havemann K. Hematopoietic reconstitution after high dose chemotherapy and autologous nonfrozen bone marrow rescue. Ann Hematol 1991;63:253-258.

3. Limón Flores JA, Castillo P, Tolama RD. Viabilidad celular en autotrasplantes utilizando refrigeración a 4 º C. Gac Med Mex 2000;136:S-217.

4. Bello C, Hermosa V, Iriondo A. Utilidad del autotrasplante de médula ósea sin criopreservación. Medicina Clínica (Barc) 1987;88:264-267.

5. Lasky LC, McCullough JM, Zanjani ED. Liquid storage of unseparate human bone marrow, evaluation of hematopoietic progenitors by clonal assay. Transfusion 1986;26:331-334.

6. Köppler H, Pflüger KH, Klausmann M, Havemann K. High dose cyclophosphamide, etoposide and BCNU with non cryopreserved autologous bone marrow transplantation for poor prognosis malignant lymphoma. Leuk Lymph 1992;6:219-222.

7. Limón Flores JA. Lo más elemental en Hematología. Universidad Autónoma de Puebla. Dirección General de Fomento Editorial, 1997;p:157-161.

8. Burnett AK, Watkins R, Maharaj D. Transplantation of unpurged autologous bone marrow in acute myeloid leukaemia in first remission. Lancet 1984;10:1068-1070.

9. Gardella S. Eliminación ex vivo de las células tumorales de la médula ósea autóloga para su utilización en autotrasplantes. Autotrasplante de médula ósea. Ediciones Doyma, 1989;p:37-47.

10. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69:585.

11. Aurer I, Gale RP. Are new conditioning regimens for transplants in acute myelogenous leukaemia better? Bone Marrow Trans 1991;7:255-261.